Sugi Predict

Sugi Predict / Compounds / SCHEMBL329758

SCHEMBL329758

SCHEMBL329758

CC(=O)NC(C(=O)O)C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 3/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PYGL P06737 7/20 0.40
▸ MMP1 P03956 2/20 0.40
▸ MMP3 P08254 1/20 0.40
▸ MMP7 P09237 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ DHODH Q02127 1/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6885724 1.00 MMP2 (0.41) MMP2CA12CA1CA2CA9
SCHEMBL3285856 1.00 MMP2 (0.41) MMP2CA12CA1CA2CA9
SCHEMBL10445869 0.98 SMN1; SMN2 (0.41) MMP2CA12CA1CA2CA9
SCHEMBL10442216 0.98 SMN1; SMN2 (0.41) MMP2CA12CA1CA2CA9
SCHEMBL19083902 0.94 SMN1; SMN2 (0.37) MMP2CA12CA1CA2CA9
SCHEMBL19083742 0.94 SMN1; SMN2 (0.37) MMP2CA12CA1CA2CA9
SCHEMBL31730569 0.90 SMN1; SMN2 (0.39) MMP2SMN1; SMN2KMT2APYGLMMP1
SCHEMBL13544389 0.90 SMN1; SMN2 (0.39) MMP2SMN1; SMN2KMT2APYGLMMP1
SCHEMBL19083735 0.90 SMN1; SMN2 (0.39) MMP2SMN1; SMN2KMT2APYGLMMP1
SCHEMBL20707095 0.83 MMP2 (0.39) MMP2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 — — US disclosed
US-11667645-B2 Granzyme B directed imaging and therapy CYTOSITE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
CN-112261939-A Granzyme B directed imaging and therapy 塞托赛特生物制药股份有限公司 2021-01-22 — — CN disclosed
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2020-11-26 — — US disclosed
CN-104263795-A Method for preparing chiral alpha-naphthenic glycine SICHUAN TONGSHENG BIOTECHNOLOGY CO LTD 2015-01-07 — — CN disclosed
CN-102020697-B Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication F. HOFFMANN-LA ROCHE LTD. (CH) 2014-10-29 — — CN disclosed
CN-103145715-A Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication HOFFMANN LA ROCHE 2013-06-12 — — CN disclosed
EP-1680137-B1 Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication HOFFMANN LA ROCHE (CH) 2012-11-21 — — EP disclosed
EP-2407470-A2 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication F. Hoffmann-La Roche Ltd. (CH) 2012-01-18 — — EP disclosed
CN-102020697-A Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication INTERMUNE INC 2011-04-20 — — CN disclosed
US-20020072613-A1 Process for producing acetophenone compound JAPAN TOBACCO INC. 2002-06-13 — — US disclosed
US-6362209-B1 ANTIPYRETICS, ANALGESICS, ANTIINFLAMMATORY AGENTS JAPAN TOBACCO INC. (JP) 2002-03-26 — — US disclosed
EP-1110955-A1 PROCESS FOR PRODUCING OXAZOLE COMPOUND JAPAN TOBACCO INC. (JP) 2001-06-27 — — EP disclosed
US-5994381-A ANTIPYRETICS; ANTIINFLAMMATORY AGENTS; ANALGESICS JAPAN TOBACCO, INC. (JP) 1999-11-30 — — US disclosed
EP-0745596-B1 HETEROAROMATIC OXAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO INC (JP) 1999-05-19 — — EP disclosed
CN-1146204-A Oxazole heterocyclic aromatic compound and use thereof JAPAN TOBACCO INC (JP) 1997-03-26 — — CN disclosed
EP-0745596-A1 HETEROAROMATIC OXAZOLE COMPOUNDS AND USE THEREOF Japan Tobacco Inc. (JP) 1996-12-04 — — EP disclosed
EP-0207580-B1 PROCESS FOR THE SYNTHESIS OF N-ACETYL AMINO ACIDS FROM OLEFINS, ACETAMIDE AND SYNGAS TEXACO DEVELOPMENT CORPORATION (US) 1989-07-26 — — EP disclosed
EP-0207580-A1 Process for the synthesis of N-acetyl amino acids from olefins, acetamide and syngas TEXACO DEVELOPMENT CORPORATION (US) 1987-01-07 — — EP disclosed
US-4267174-A AND PROCESS FOR ADMINISTERING BOEHRINGER MANNHEIM, GMBH (DE) 1981-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB MMP2 276/4885CA12 724/4885CA1 1536/4885
US-20020072613-A1 Process for producing acetophenone compound CBR3, AGPAT5, AKR1C4 MMP2 4256/4885CA12 3007/4885CA1 1897/4885
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB MMP2 276/4885CA12 724/4885CA1 1536/4885
US-11667645-B2 Granzyme B directed imaging and therapy GZMB, PRF1, CTSB MMP2 276/4885CA12 724/4885CA1 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.